UB Paderborn / Katalog / Suche / in CDI

Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the ‘burden of therapy’ method

European journal of cancer (1990), 2021-03, Vol.146, p.95-106

2021

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the ‘Arbeitsgemeinschaft Internistische Onkologie’

European journal of cancer (1990), 2018-05, Vol.94, p.95-103

2018

Link zum Volltext

Verfügbarkeit prüfen

P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate

Leukemia, 2004-03, Vol.18 (3), p.401-408

2004

Link zum Volltext

Verfügbarkeit prüfen

Gemcitabine plus afatinib versus gemcitabine alone in metastatic pancreatic cancer: An explorative randomized AIO phase II trial (ACCEPT)

Annals of oncology, 2018-10, Vol.29, p.viii243-viii243

2018

Link zum Volltext

Verfügbarkeit prüfen

Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparations

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2004-01, Vol.799 (1), p.23-36

2004

Link zum Volltext

Verfügbarkeit prüfen

Dose-reduced conditioning for allogeneic blood stem cell transplantation : durable engraftment without antithymocyte globulin

Bone marrow transplantation (Basingstoke), , Vol.26 (2), p.119-125

Link zum Volltext

Verfügbarkeit prüfen

Dose-reduced Conditioning and Allogeneic Hematopoietic Stem Cell Transplantation from Unrelated Donors in 42 Patients

Clinical cancer research, 2001-08, Vol.7 (8), p.2254-2262

2001

Link zum Volltext

Verfügbarkeit prüfen

Targeting mycophenolate mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation

Bone marrow transplantation (Basingstoke), 2008-07, Vol.42 (2), p.113-120

2008

Link zum Volltext

Verfügbarkeit prüfen

Buccal swabs but not mouthwash samples can be used to obtain pretransplant DNA fingerprints from recipients of allogeneic bone marrow transplants

Bone marrow transplantation (Basingstoke), 2000-03, Vol.25 (5), p.575-577

2000

Link zum Volltext

Verfügbarkeit prüfen

Targeting once-daily intravenous busulfan in combination with fludarabine before allogeneic hematopoietic cell transplantation

Bone marrow transplantation (Basingstoke), 2005-03, Vol.35 (6), p.627-628

2005

Link zum Volltext

Verfügbarkeit prüfen

Accidental busulfan overdose during conditioning for stem cell transplantation

Bone marrow transplantation (Basingstoke), 2005-01, Vol.35 (2), p.125-128

2005

Link zum Volltext

Verfügbarkeit prüfen

Acute heart failure after allogeneic blood stem cell transplantation due to massive myocardial infiltration by cytotoxic T cells of donor origin

Bone marrow transplantation (Basingstoke), 2001, Vol.27 (1), p.107-109

2001

Link zum Volltext

Verfügbarkeit prüfen

Double lumen port access in patients receiving allogeneic blood stem cell transplantation

Bone marrow transplantation (Basingstoke), 2001-12, Vol.28 (11), p.1067-1072

2001

Link zum Volltext

Verfügbarkeit prüfen

Imatinib mesylate selectively influences the cellular metabolism of cytarabine in BCR/ABL negative leukemia cell lines and normal CD34+ progenitor cells

Annals of hematology, 2004, Vol.83 Suppl 1, p.S61-S64

2004

Link zum Volltext

Verfügbarkeit prüfen

Treatment of relapsing leukemia after allogeneic blood stem cell transplantation by using dose-reduced conditioning followed by donor blood stem cells and GM-CSF

Annals of hematology, 2001-03, Vol.80 (3), p.144-149

2001

Link zum Volltext

Verfügbarkeit prüfen

Early allogeneic blood stem cell transplantation after modified conditioning therapy during marrow aplasia: stable remission in high-risk acute myeloid leukemia

Bone marrow transplantation (Basingstoke), 2001-03, Vol.27 (5), p.543-546

2001

Link zum Volltext

Verfügbarkeit prüfen

Dosisintensität und Zelltod

Onkologie (Heidelberg, Germany), 1999-05, Vol.5 (5), p.450-455

1999

Link zum Volltext

Verfügbarkeit prüfen

Elimination of imatinib mesylate and its metabolite N-desmethyl-imatinib

Journal of clinical oncology, 2005-06, Vol.23 (16), p.3855-3856

2005

Link zum Volltext

Verfügbarkeit prüfen

CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid

Annals of hematology, 2004-06, Vol.83 (6), p.401-402

2004

Link zum Volltext

Verfügbarkeit prüfen

Successful preemptive cidofovir treatment for CMV antigenemia after dose-reduced conditioning and allogeneic blood stem cell transplantation

Transplantation, 2001-04, Vol.71 (7), p.880

2001

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of intravenous mycophenolate mofetil after allogeneic blood stem cell transplantation

Clinical transplantation, 2001-06, Vol.15 (3), p.176-184

2001

Link zum Volltext

Verfügbarkeit prüfen

Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin

Bone marrow transplantation (Basingstoke), 2000-07, Vol.26 (2), p.119-125

2000

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the ‘burden of therapy’ method

Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the ‘Arbeitsgemeinschaft Internistische Onkologie’

P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate

Gemcitabine plus afatinib versus gemcitabine alone in metastatic pancreatic cancer: An explorative randomized AIO phase II trial (ACCEPT)

Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110)

Age and RAS status to select patients with metastatic colorectal cancer (mCRC) for initial sequential versus combination therapy including fluoropyrimidines (FP), irinotecan (Iri) and bevacizumab (Bev): XELAVIRI- study

Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparations

Dose-reduced conditioning for allogeneic blood stem cell transplantation : durable engraftment without antithymocyte globulin

Dose-reduced Conditioning and Allogeneic Hematopoietic Stem Cell Transplantation from Unrelated Donors in 42 Patients

Targeting mycophenolate mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation

Buccal swabs but not mouthwash samples can be used to obtain pretransplant DNA fingerprints from recipients of allogeneic bone marrow transplants

Targeting once-daily intravenous busulfan in combination with fludarabine before allogeneic hematopoietic cell transplantation

Accidental busulfan overdose during conditioning for stem cell transplantation

Acute heart failure after allogeneic blood stem cell transplantation due to massive myocardial infiltration by cytotoxic T cells of donor origin

Double lumen port access in patients receiving allogeneic blood stem cell transplantation

Imatinib mesylate selectively influences the cellular metabolism of cytarabine in BCR/ABL negative leukemia cell lines and normal CD34+ progenitor cells

Treatment of relapsing leukemia after allogeneic blood stem cell transplantation by using dose-reduced conditioning followed by donor blood stem cells and GM-CSF

Early allogeneic blood stem cell transplantation after modified conditioning therapy during marrow aplasia: stable remission in high-risk acute myeloid leukemia

Dosisintensität und Zelltod

Elimination of imatinib mesylate and its metabolite N-desmethyl-imatinib

Sequential first-line therapy of metastatic colorectal cancer (mCRC) starting with fluoropyrimidine (FP) plus bevacizumab (BEV) vs. initial FP plus irinotecan (IRI) and BEV: German AIO KRK0110 (ML22011) study

CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid

Successful preemptive cidofovir treatment for CMV antigenemia after dose-reduced conditioning and allogeneic blood stem cell transplantation

Pharmacokinetics of intravenous mycophenolate mofetil after allogeneic blood stem cell transplantation

Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin

Suchergebnisse filtern